Drug Discovery World
MAY 21, 2024
Ben Holland , CTO and Co-Founder of Antiverse discusses how artificial intelligence and machine learning are benefitting antibody discovery and design. Modern experimental procedures, such as immunisation, B-cell screening, and synthetic library generation, have been pivotal in developing approximately 80 FDA-approved antibody therapeutics.
Drug Discovery World
MARCH 29, 2023
The trial is expected to enrol 10 patients, aged 18-75 years, who have had a diagnosis of medically refractory UC of at least six months duration and have failed at least one monoclonal antibody therapy. The post First patient dosed in ulcerative colitis drug trial appeared first on Drug Discovery World (DDW).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioSpace
APRIL 1, 2021
One of the common research approaches to treating brain diseases such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) is using antibodies designed to clear the accumulated misfolded proteins implicated in the diseases. To date, these drug trials have not been particularly successful at i.
Drug Discovery World
FEBRUARY 20, 2023
AstraZeneca’s Evusheld became the first antibody combination for pre-exposure prophylaxis (PrEP) against Covid-19 licensed in the UK. Prostate cancer A new metastatic prostate cancer drug was approved by the FDA in March, followed by the European Commission in December.
pharmaphorum
JANUARY 25, 2021
GlaxoSmithKline has suffered another research setback after it axed a phase 2 trial of an anti-LAG3 drug in patients with ulcerative colitis, following a major disappointment with a key lung cancer drug last week. The post GSK suffers another R&D setback, axing ulcerative colitis drug trial appeared first on.
The Pharma Data
NOVEMBER 10, 2020
“They will help researchers mechanistically assess target engagement in clinical trials,” and also will be used in clinical practice to identify the right drugs for the right patients, Howard Fillet, M.D., We wanted a tau antibody that would bind to the expressed forms of tau, so we developed a very specific assay,” Dage said.
Advarra
MARCH 21, 2023
While drugs require Phase I-III clinical trials—and are also subject to post-approval tracking—digital therapeutics, devices, and IVDs may be able to leverage bench testing, animal studies, pilot studies, and training sets. Class 3: Applied to products with the highest risk, or to Class 2 products that are the first in their category.
Expert insights. Personalized for you.
59 
Let's personalize your content